文献速递肝病

肝硬化及肝性脑病患者细菌宏基因组与病毒组的相互作用

Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
PubMed 文献 · Gut · 2020-09-30

本研究纳入40名对照和163例肝硬化门诊患者(63例代偿期、43例拉鲁肽治疗、57例利福昔明治疗),并进行利福昔明前后8周队列比较。结果显示粪便噬菌体与肝硬化特征及90天住院结局关联稀疏,而以产尿素酶链球菌为中心的噬菌体-细菌连接受疾病进展和利福昔明治疗影响,并在90天住院患者中发生改变。

要点

  • 肝硬化患者细菌α/β多样性从对照至利福昔明组逐渐恶化,噬菌体β多样性组间不同但α多样性相似。
  • 拉鲁肽组90天住院率高于利福昔明组(56% vs 30%,p=0.008)。
  • 利福昔明前后8周噬菌体和细菌α/β多样性均无变化,但以产尿素酶链球菌为中心的噬菌体-细菌连接在利福昔明后瓦解。

核心结论

  • 与细菌不同,粪便噬菌体与肝硬化特征及90天结局关联稀疏。
  • 以产尿素酶、产氨链球菌为中心的噬菌体与细菌连接受疾病进展和利福昔明治疗影响,并在90天住院患者中发生改变。

研究设计与样本

  • 横断面和利福昔明前后队列研究。
  • 横断面队列纳入对照和肝硬化门诊患者(代偿期、拉鲁肽治疗、利福昔明治疗),随访90天住院情况。
  • 前后队列为代偿期肝硬化患者,在利福昔明治疗8周前后采集粪便。
  • 对粪便进行细菌和噬菌体宏基因组分析及相关性网络分析。

主要发现

  • 横断面纳入40名对照和163例肝硬化患者(63例代偿期、43例拉鲁肽、57例利福昔明)。
  • 拉鲁肽组与利福昔明组MELD评分相似,但拉鲁肽组90天住院率高于利福昔明组(56% vs 30%,p=0.008)。
  • 细菌α/β多样性从对照至利福昔明组逐渐恶化;噬菌体α多样性相似,β多样性组间不同。
  • 自体细菌与MELD负相关,致病菌与MELD正相关,噬菌体与MELD仅见微弱相关。
  • 噬菌体-细菌相关网络复杂度在对照最高,拉鲁肽组最低,利福昔明组升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Altered bacterial composition is associated with disease progression in cirrhosis but the role of virome, especially phages, is unclear. DESIGN: Cross-sectional and pre/post rifaximin cohorts were enrolled. Cross-sectional: controls and cirrhotic outpatients (compensated, on lactulose (Cirr-L), on rifaximin (Cirr-LR)) were included and followed for 90-day hospitalisations. Pre/post: compensated cirrhotics underwent stool collection pre/post 8 weeks of rifaximin. Stool metagenomics for bacteria and phages and their correlation networks were analysed in controls versus cirrhosis, within cirrhotics, hospitalised/not and pre/post rifaximin. RESULTS: Cross-sectional: 40 controls and 163 cirrhotics (63 compensated, 43 Cirr-L, 57 Cirr-LR) were enrolled. Cirr-L/LR groups were similar on model for end-stage liver disease (MELD) score but Cirr-L developed greater hospitalisations versus Cirr-LR (56% vs 30%, p=0.008). Bacterial alpha/beta diversity worsened from controls through Cirr-LR. While phage alpha diversity was similar, beta diversity was different between groups. Autochthonous bacteria linked negatively, pathobionts linked positively with MELD but only modest phage-MELD correlations were seen. Phage-bacterial correlation network complexity was highest in controls, lowest in Cirr-L and increased in Cirr-LR. Microviridae and Faecalibacterium phages were linked with autochthonous bacteria in Cirr-LR, but not Cirr-L hospitalised patients had greater pathobionts, lower commensal bacteria and phages focused on Streptococcus, Lactococcus and Myoviridae. Pre/post: No changes in alpha/beta diversity of phages or bacteria were seen postrifaximin. Phage-bacterial linkages centred around urease-producing Streptococcus species collapsed postrifaximin. CONCLUSION: Unlike bacteria, faecal phages are sparsely linked with cirrhosis characteristics and 90-day outcomes. Phage and bacterial linkages centred on urease-producing, ammonia-generating Streptococcus species were affected by disease progression and rifaximin therapy and were altered in patients who experienced 90-day hospitalisations.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Bajaj JS, Sikaroodi M, Shamsaddini A, et al. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. Gut. 2020. PMID: 32998876. doi:10.1136/gutjnl-2020-322470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。